Daily Archives: March 20, 2020

Junshi Biosciences Announces Co-Development Agreement with IMCAS to Advance Neutralizing Antibodies as Potential Novel Treatment for COVID-19

SHANGHAI, China, March 20, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEK: 1877) announced that it has recently signed a collaboration agreement with the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) to jointly develop neutralizing antibodies, a potential novel treatment for COVID-19.

Junshi Biosciences and IMCAS have been working together to explore innovative treatments for the novel coronavirus, COVID-19. Currently, they have obtained multiple strains of neutralizing antibodies (NAb) capable of effectively blocking viral invasion in laboratory assays and have conducted animal experiments. Preliminary in vitro and in vivo studies have verified the blocking activity of the NAb strains. It is in the process of verifying the preclinical toxicology and in vivo activity of the antibodies in order to file Investigative New Drug (IND) applications with domestic and overseas regulatory agencies.

A neutralizing antibody (NAb) is an antibody capable of keeping an infectious agent, usually a virus, from infecting a cell by neutralizing or inhibiting its biological effect. It could potentially facilitate virus clearance, altering the course of infection. Antibody-based therapies have several advantages: they can be therapeutic as well as prophylactic, protecting health workers in a high-risk environment; they are generally safe given their specificity to pathogen; and compared with the serum of recovered patients, antibodies are more consistent in quality and can be readily mass-produced through biological engineering, thereby ensuring ample clinical supply for the pandemic.

As a leading pharmaceutical innovator in China specialized in therapeutic antibody development, Junshi Biosciences has established long-term cooperation with IMCAS with its proprietary antibody development platform to carry out screening for various pathogen host receptors and anti-pathogen antibodies, from patients recovered from the infection. Since the very beginning of the COVID-19 outbreak, these two parties have been actively collaborating to combat the epidemic and develop neutralizing antibodies.

Dr. Ning Li, CEO of Junshi Biosciences, commented, “There has not yet been an effective antibody drug approved for treating the novel coronavirus in humans. It is our responsibility as a local pharmaceutical innovator to harness our proprietary antibody platform and R&D capabilities to diligently develop a treatment in the near-future. We believe our collaboration with IMCAS will help accelerate the clinical development of an antibody therapy. We look forward to facilitating the use of antibody-based therapy as a treatment option for COVID-19, both in China and globally.”

About Junshi Biosciences

Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with treatment options that work better and cost less. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 1877.HK. The Company has established a diversified R&D pipeline comprising 20 drug candidates with therapeutic areas covering anti-tumor, metabolic diseases, autoimmune diseases, and neurologic diseases. Product types include monoclonal antibodies, fusion proteins, ADCs, and small molecule drugs. With a 33,000L fermentation capacity of biopharmaceutical production established in Shanghai and Wujiang by the end of 2019, we will satisfy the needs for commercialization and provide our partners and patients with a global supply chain network.


The Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) was founded on December 3, 1958, through the merger of the Institute of Applied Mycology and the Beijing Laboratories of Microbiology, both of which were affiliated to the Chinese Academy of Sciences (CAS). After over 50 years of development, it has become the nation’s largest comprehensive research institution of microbiological science with 5 State and CAS key laboratories. IMCAS owns the largest fungal herbarium in Asia with nearly 500,000 specimens and the largest microbiological culture collection in China with more than 41,000 strains. In addition, it possesses a microbiological information center, a core facility, a Biosafety Level-3 laboratory and other supporting platforms.

Contact Information

IR Team:
+ 86 021-2250 030

Solebury Trout
Michael Levitan
+1 646-378-2920

CNH Industrial announces two week suspension of its assembly operations in Europe in response to the COVID-19 pandemic

London, 20 March 2020

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announced today that, in light of the supply chain constrains caused by the COVID-19 emergency in Europe, it is suspending the majority of its European assembly operations for a two week period. This suspension applies to the Company’s agricultural, construction, commercial and specialty vehicles production facilities. Most component facilities will remain operational at low speed, always in strict compliance with national health directives, in order ensure the continuation of supply to the Company’s manufacturing facilities located outside of Europe. European parts depots and most dealer locations will also remain open to maintain uninterrupted service to its customer base. CNH Industrial is working in close consultation with unions and works councils to implement the temporary shut downs and the re-opening of the plants.

“The Company takes the health and wellbeing of its entire workforce very seriously, and we have implemented all measures to protect the employee population, as well as to help in the fight to contain the spread of the pandemic,” said Hubertus Mühlhäuser, Chief Executive Officer, CNH Industrial. “The decision to shut down our European assembly plants for a two week period is driven by disruptions in our European supply chain, that do not allow for an efficient operation. During these temporary shutdowns, we will also undertake further extensive sanitization and deep cleaning procedures” concludes Mr. Mühlhäuser.

Alongside these measures, and those already in place at the Company’s locations around the world, the CNH Industrial’s COVID-19 global taskforce is constantly monitoring the situation in all markets in which it operates, and will take further measures as required, while continuing to respond to end market demand and service requirements for its mission critical capital goods.

CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com


Corporate Communications

Email: mediarelations@cnhind.com

Investor Relations

Email: investor.relations@cnhind.com


Taconic Biosciences Supports Coronavirus Research

Announces Preclinical COVID-19 Research Tools

RENSSELAER, N.Y., March 20, 2020 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces support for global COVID-19 research efforts via a new Coronavirus Toolkit featuring relevant models and services.

Mouse models have been extensively used for research on the SARS-CoV virus, closely related to the new SARS-CoV-2 virus that causes COVID-19.  Taconic offers many animal models and services to support COVID-19 research and empower the global fight against this disease.

Taconic’s Coronavirus Toolkit models are grouped by application: COVID-19 disease models, antibody development and production, and vaccine research and development.

The toolkit includes several proprietary models, one example being an Ace2 knockout mouse available to Taconic through our partnership with inventor Lexicon Pharmaceuticals.  Ace2 knockout mice are used to study acute respiratory distress syndrome (ARDS), a COVID-19 complication.  Taconic and Lexicon have partnered to scale production of this strain with subsidized distribution to researchers worldwide.  A second example includes genetically humanized HLA (human leukocyte antigen) mice, which are better able to model human vaccine response compared to standard mice.  Finally, Taconic is one of only a few companies in the world which can produce humanized immune system mice on scale, which carry human immune cells in a mouse.

Beyond models, Taconic’s colony management solutions also offer relief to laboratories faced with restrictions, staff reductions, or temporary closures.  Cryopreservation services are offered at a highly competitive price to ensure the security of valuable genetically modified models for the future.  As research priorities change, Taconic also encourages researchers to consider custom model generation as a path to move research forward without requiring extensive internal human resources.  Taconic has the most comprehensive, fully-licensed gene modification toolkit in the industry.

“Taconic is proud to contribute to the global fight against the coronavirus pandemic.  We take our mission to provide animal model solutions seriously and are committed to empowering COVID-19 research,” shared Nancy J. Sandy, Taconic Biosciences’ chief executive officer. “We are investing significant resources to make these critical models available to enable immediate studies.”

To learn more about Taconic Biosciences’ Coronavirus Toolkit, please contact Taconic at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact: Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824